Lionheart Health Primary Product Portfolio

25 product families • Evidence and related intellectual property • October 9 2026

Lionheart combines programmable bioelectric protein signaling with exercise, biologics and organ-directed delivery. This summary includes every requested offering, grouping exosomes with peptides and Klotho Bioreactor with KlothoImplant. Reported early results do not establish efficacy of the complete Plus combinations.

Product family	Purpose and supporting data	Related patents and IP status
1 BodStim™	EMS exercise and muscle platform. Reported 12-week gains: walk distance 8–18%, grip strength 8–15%, leg power 10–25%. Medical applications remain investigational. [1]	Related Klotho patents US 11,471,686 / 12,226,639; bioelectric protein-expression platform.
2 HairCell™ Plus	Bioelectric signaling plus light, PEMF, serums, seven-peptide stack and optional PRF. Early reported hair-density gains: 16.7% at 4 weeks; ~30% at 12 weeks. [2]	Related protein-signaling and Klotho IP; newer hair-related filings reported. Complete Plus coverage not mapped.
3 SkinStim™ Plus	Bioelectric, PRF, light, PEMF, EMS and topicals. Cultured skin-cell mRNA: elastin +18%, collagen I +35.4%, III +44%, Klotho +420%; small case reports. [3]	Related bioelectric / Klotho estate; laboratory gene-expression findings are not patient protein gains.
4 ErectiStim™ and FemStim™	Sexual and pelvic-health programs targeting circulation, tissue quality and function. Early-stage research; no verified product-specific outcome dataset reviewed. [2]	Related vascular elasticity US 11,167,141 and Klotho IP; indication-specific claim mapping needed.
5 EyeCell™ Plus and EyeCell Skaphor	Vision-support combination. Early EyeCell series: 16 eyes; 68.7% improved, 18.8% stable, up to 4 acuity lines gained. Not evidence for each Skaphor component. [2]	Related Klotho and regenerative signaling IP; separate Skaphor rights not verified.
6 OrthoStim™ Plus	Joint and musculoskeletal program. Early selected-subject results: pain −40–65%, WOMAC improvement 35–50%, six-minute walk +12–22%. [2]	Related regenerative bioelectric IP; OPG US 11,691,007. Full combination coverage not verified.
7 Second Brain™ Plus Gut Health	Gut–brain platform combining bioelectric stimulation, microbiome support and investigational biologics. No quantified proprietary clinical outcomes verified. [2,4]	Company cites inflammation / neuromodulation IP; specific claims and license scope require confirmation.
8 Lionheart Klotho-Up™ Protocol	Integrated muscle, brain and immune healthspan study: diet, BodStim, supplements, testing and optional modalities. Early company pilot reports require source-data confirmation.	Related issued Klotho patents; FOXO3–AMPK–mTOR provisional reported. Protocol-wide patent protection not established.
9 SynovaWave™	Distributed bedside adipose-tissue processor for regenerative research workflows. Historical cell-therapy results do not validate this processor or every downstream use. [5]	Supplier technology and rights; Lionheart-owned processor patent not verified.
10 BioPRF	Autologous platelet-rich fibrin preparation; bioelectric conditioning is being studied to enhance signaling. Incremental clinical benefit remains unconfirmed. [3,6]	Company describes bioelectric PRF as patent pending; application number and claim scope not verified.
11 Bioelectric enhanced exosomes and peptides	Investigational conditioning / delivery intended to improve biologic activity or peptide uptake. Separate controlled human combination outcomes not verified. [3,5,7]	Peptide-enhancement filing reported as pending; exosome-specific filing and claims require confirmation.
12 Lionheart Octopus™	Refillable pump plus programmable stimulation and biologic delivery for multiple organs. Engineering-stage platform; no demonstrated total-organ regeneration. [8]	Related issued Stimulator, pump and composition patent US 10,646,644; newer system filings reported.
13 KlothoPatch™ I and II	I: wearable delivery / stimulation concept. II: organ-surface cell–hydrogel bioreactor with membrane and refill system. Human outcomes not established. [9,10]	Related Klotho / pump IP; II provisional described as prepared Sept. 22, 2026, not verified filed. [9]

Lionheart Health Portfolio Continued

Product family	Purpose and supporting data	Related patents and IP status
14 KlothoPod™ I and II	Klotho-focused wellness / multimodality platforms. Device configurations vary by generation; no controlled outcomes specific to either complete Pod verified. [10]	Related Klotho estate; distinct I / II issued device claims not verified.
15 BioLeonhardt Whole Body Regeneration Chamber	"Womb for Adults" concept for integrated whole-body regenerative support. Research-stage offering; no verified human regeneration dataset.	Proposed bioelectric, delivery and biologic IP; dedicated chamber filing / grant not verified.
16 Klotho Bioreactor™ and KlothoImplant™	Cell-based Klotho production and implantable delivery concepts. Intended sustained localized signaling; clinical durability and safety remain to be established. [9,10]	Related Klotho and pump patents; cell-platform license documentation and product claims need review.
17 Klotho NanoFlowers™	Investigational nanoscale Klotho-support / delivery concept. No verified product-specific human outcomes or validated clinical dose. [10]	Dedicated NanoFlowers filing / issued claims not verified; related Klotho IP is not proof of coverage.
18 KidneyCell™ Plus	Renal bioelectric / biologic regeneration program targeting Klotho and tissue repair. No verified complete-Plus human renal outcome dataset. [2]	Directly related Kidney treatment patent US 11,446,488; issued Klotho families.
19 LiverCell™ Plus	Bioelectric liver-repair program with proposed macrophages, Klotho, nutrient hydrogel and controlled delivery. Development-stage combination. [11]	Related Klotho and pump patents; liver-specific combination claims / filing status not verified.
20 PancreaCell™ Plus	Pancreatic regeneration concept combining stimulation and biologic support. No verified human insulin-restoration or diabetes-reversal dataset. [9]	Related bioelectric, Klotho and pump estate; pancreatic indication claim mapping needed.
21 Brain Band™ software family	DepressiStim™, CerebraCell Brain-N-Hance™, MemoryStim™, AddictiStim™. Early program reports: memory +12–34%, attention +15–30%, mood +18–35%, stress −15–45%. [12]	Related Klotho / neurotrophic signaling IP. Program-level results do not establish each software indication.
22 KlothoGeno™	Klotho gene therapy in encapsulated, immune-protected cell packages. Proposed durable biologic production; no verified outcomes for this exact packaged product.	Gene-engineered cell / encapsulation rights and dedicated filing status require documentation; related Klotho IP alone is insufficient.
23 BioLeonhardt™ Total Heart Regeneration	Cardiac bioelectric + biologic delivery platform. Builds on team MyoCell clinical experience; historical cell trials do not prove this new complete system. [2,8]	Related US 10,646,644 and cardiac bioelectric US 12,109,410; Klotho estate.
24 VascuStim™	Wound / vascular repair program. Historical reports: 8/8 patients had accelerated wound progression; separate cell series: 12/16 avoided anticipated amputation. [5]	Related stem-cell homing / angiogenesis IP, pump US 10,646,644 and vascular US 11,167,141.
25 EarCell™ Plus	Hearing-recovery research targeting cochlear cells, neurotrophic pathways and synaptic health. Translational rationale; no verified proprietary human hearing-recovery outcomes. [2,13]	Related regenerative signaling / Klotho IP; dedicated hearing-specific issued claim scope not verified.

Evidence and IP notes Results are company-reported early clinical observations or laboratory findings, not independent verification. "Related" identifies technology families, not a legal opinion that every product falls within issued claims. Provisional or planned filings are not issued patents. Commercial devices and investigational disease-treatment combinations have different regulatory status. Management reports Lionheart commercialization rights to the relevant Leonhardt estate; executed rights schedules were not audited here.

[1] BodStim results [2] Portfolio data [3] SkinStim findings [4] Second Brain [5] VascuStim data [6] BioPRF description [7] Peptide program [8] Octopus and IP [9] KlothoPatch II [10] Klotho concepts [11] LiverCell development [12] Brain Band results [13] EarCell research